Recent 8-K filings for SGMO

• May 14, 2026, 4:02 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB

  Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.

• April 29, 2026, 7:59 PM ET regulatory materiality 0.75 negative item 8.01

  Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026

  Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.

• March 30, 2026, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing

  Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).

• February 4, 2026, 6:59 PM ET other material materiality 0.75 negative item 1.01item 3.02item 9.01 ◈ Material Agreements

  Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants

  Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.

• February 3, 2026, 6:59 PM ET other material materiality 0.85 negative item 2.02item 5.02

  Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed

  Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).

• February 3, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01

  Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path

  FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment

  Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.

• October 29, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices ×2

  Sangamo gets Nasdaq extension to April 27, 2026 to meet $1.00 bid price

  Received 180-day extension from Nasdaq until April 27, 2026 to regain minimum bid price compliance.

• September 30, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Sangamo CFO Duraibabu resigns effective Oct 1, stays part-time; Jain new principal accounting officer

  CFO Duraibabu resigns effective Oct 1, 2025; transitions to part-time principal financial officer role.

• September 11, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025

  Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.

• September 4, 2025, 7:59 PM ET other material materiality 0.80 neutral item 8.01

  Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026

  Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.

• August 7, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M

  Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.

• June 24, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026

  Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.

• June 16, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Sangamo stockholders approve 14M share increase to 2018 equity plan

  Share reserve increased by 14,000,000 shares; total now includes 8.8M, 9.9M, 7.9M, 10M, 11M from prior years.

• May 13, 2025, 7:59 PM ET other materiality 0.65 neutral item 8.01item 9.01

  Sangamo Therapeutics raises ~$23M in underwritten public offering of common stock and warrants

  Offering of 12.2M shares and pre-funded warrants for 34.4M shares, each with accompanying purchase warrant, at $0.50 unit price.

• May 6, 2025, 7:59 PM ET other material materiality 0.75 negative item 3.01

  Sangamo receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

  On April 30, 2025, Nasdaq notified Sangamo that its stock closed below $1.00 for 30 consecutive business days.

• March 17, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval

  FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.

• February 6, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01

  Sangamo reports updated Phase 1/2 STAAR data for ST-920; eGFR slope +3.061; FDA Accelerated Approval path confirmed

  33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.

• December 30, 2024, 6:59 PM ET other material materiality 0.85 negative item 1.02

  Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost

  Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.

• December 10, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved

  Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).

• November 12, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Sangamo posts Q3 net income $10.7M; FDA clears Accelerated Approval path for Fabry gene therapy ST-920

  Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.

• October 4, 2024, 7:59 PM ET litigation materiality 0.70 negative item 7.01item 9.01

  Sangamo files to validate share increase; stockholder challenge; hearing Dec 12

  Stockholder lawsuit claims wrong voting standard for share increase; company seeks validation.

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B

  Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.

• July 24, 2024, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis

  AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.

• June 5, 2024, 7:59 PM ET other materiality 0.50 neutral item 5.02item 5.03item 5.07item 9.01

  Sangamo shareholders approve increase in authorized shares and equity plan share reserve at annual meeting

  Authorized common stock increased from 640M to 960M shares (320M increase).

• May 9, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024

  Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.

• April 30, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Sangamo receives Nasdaq deficiency notice for bid price below $1 per share

  Notice received April 24, 2024; stock closed below $1 for 30 consecutive business days.

• March 25, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants

  Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event other_material

8 positive 12 negative 8 neutral

source · SGMO on sec.gov